Spring shoppers pick up discount deals
This article was originally published in Scrip
The announcements this week of the acquisitions of Cambridge UK-based Astex Therapeutics by SuperGen, and Inspire Pharmaceuticals by Merck might be heralded as the long-awaited thaw in the sector, another symptom of which has been the lack of initial public offerings. Both transactions however, together with the US IPO of Tranzyme however, more closely represent a continuation of the distinctly chilly backdrop for the life science space.
You may also be interested in...
Deals announced by Sanofi and Novartis at this year’s virtual J.P. Morgan Healthcare Conference and a smattering of full-year revenue preannouncements did not mark a bumper start to the year.
A positive start to the year for healthcare stocks was accompanied, as usual, by drug price increases. This and the other issues that have been carried over from 2020 remain just as challenging.
Agios’s divestment of its oncology pipeline and commercial operations provided a rare case where all parties appeared satisfied. In many other cases, there are winners and losers.